| Similar Articles |
|---|
 |
The Motley Fool
March 4, 2005
Rich Duprey |
Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails.   |
The Motley Fool
October 29, 2004
W.D. Crotty |
Future Looking Up for Flamel As the nanotech/biotech company earns a profit -- keep an eye on two drugs in phase 3 trials. |
The Motley Fool
June 6, 2005
Rich Duprey |
Flamel Inflames Passions The nanotech firm faces a fiery shareholder fight. Is Flamel doing enough to promote its medical technologies? Management says yes, but shareholders disagree. Here's a survey of the battlefield. |
The Motley Fool
September 6, 2005
Rich Duprey |
Flamel's Dubious Future French nanotech pioneer loses deal with TAP Pharmaceuticals for heartburn formulation. There's just too much fog facing this company for investors to see clearly ahead. |
The Motley Fool
October 25, 2005
Jason Mac Gurn |
Visualizing Value for Flamel Those interested in the long-term potential of this biotech's business should be searching for signs that its technological potential will evolve to provide value for shareholders. |
The Motley Fool
July 30, 2004
W.D. Crotty |
This Nanotech Deserves Respect While the stock recently hit some potholes, Flamel still looks good for the future. |
The Motley Fool
June 15, 2005
Charly Travers |
Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success. |
The Motley Fool
September 14, 2007
Brian Lawler |
Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret. |
The Motley Fool
September 27, 2005
Jack Uldrich |
A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead. |
The Motley Fool
June 14, 2005
Bill Mann |
It's Time for a Change at Flamel A dissident shareholder believes that the French medical tech company's management needs shaking up. Reluctantly, we agree. |
The Motley Fool
July 8, 2004
W.D. Crotty |
From Flameout to Bargain Despite its stock decline, there's a lot to like about French biopharmaceutical Flamel. |
The Motley Fool
August 27, 2007
Rich Duprey |
Flamel Falls Out of Compliance Market lashes out after a patient-compliance study shows that its only drug offers no better solution. Flamel has always been a risky investment, and that hasn't changed. |
The Motley Fool
December 26, 2007
Brian Lawler |
Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment. |
The Motley Fool
December 21, 2007
Brian Lawler |
Flamel Wheeling and Dealing Flamel announces very few details about it's latest deal, this time with German drugmaker Merck KGaA. |
The Motley Fool
June 23, 2005
Bill Barker |
History Is Made, for Now At yesterday's annual meeting, Flamel's shareholders made history. All proposals to re-elect the former directors were rejected by voting shareholders. |
The Motley Fool
May 15, 2008
Brian Lawler |
What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority. |
The Motley Fool
November 2, 2007
Brian Lawler |
Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note. |
The Motley Fool
December 12, 2008
Brian Orelli |
An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb. |
The Motley Fool
March 5, 2008
Brian Lawler |
Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline. |
The Motley Fool
July 29, 2004
Brian Gorman |
Bristol-Myers Bottoming Out? The pharmaceutical company's expectations are in doubt, but investors might want to focus on its potential. |
The Motley Fool
August 8, 2008
Brian Lawler |
Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline. |
The Motley Fool
April 28, 2008
Brian Lawler |
Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another. |
The Motley Fool
December 18, 2006
Brian Lawler |
Nice: Flamel's Drug Approval With so much pessimism and internal hullabaloo, there weren't many investors willing to stick with Flamel, but those who did have been rewarded nicely. |
The Motley Fool
January 27, 2005
Wherrett & Yelovich |
Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look. |
The Motley Fool
January 28, 2009
Brian Orelli |
A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer. |
The Motley Fool
September 20, 2004
Rich Duprey |
Is Unilever Taking a Bath? The consumer products conglomerate warns of lowers sales and profits. |
The Motley Fool
February 11, 2008
Brian Lawler |
No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker. |
The Motley Fool
July 31, 2006
Stephen D. Simpson |
More Plavix Headaches for Bristol-Myers Problems with a Plavix settlement put a large chunk of earnings at risk. Investors, take note. |
The Motley Fool
October 25, 2007
Brian Lawler |
Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note. |
The Motley Fool
January 6, 2005
Rich Duprey |
Bristol-Myers Relieves Its Headache The pharmaceutical giant is selling its consumer medicines division. Though the division represents only about 2% of Bristol-Myers' $21 billion sales, the company overall has seen sales falter and its stock decline some 12% last year. |
The Motley Fool
April 28, 2008
Brian Lawler |
Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after. |
The Motley Fool
October 28, 2005
Stephen D. Simpson |
Bristol-Myers' Bad Mojo The possible loss of the experimental diabetes drug Pargluva is a blow to this pharmaceutical that's already hurting for growth. If you're expecting a near-term bang for your investment buck, this might not be the best destination. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Bristol-Myers: Hang in There Generics are wreaking havoc on growth, but patient investors can pin hopes on drugs now in the pipeline. |
The Motley Fool
May 14, 2007
Brian Lawler |
Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note. |
The Motley Fool
July 10, 2007
Brian Orelli |
Sometimes, the Same Is Good Enough Bristol-Myers Squibb's new drug doesn't work better, but it's easier to take. Investors, take note. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
The Motley Fool
October 26, 2007
Brian Lawler |
Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note. |
IndustryWeek
April 1, 2007
Traci Purdum |
Beaker Counters Bristol-Myers Squibb incorporates procurement initiative. |
The Motley Fool
November 24, 2004
Wherrett & Yelovich |
The Tiny Next Big Thing As nanotechnology evolves, the smart investor will keep an eye on the players most likely to be left standing -- and making money. |
The Motley Fool
April 7, 2009
Brian Orelli |
Bristol-Myers Squibb: On the Patent Cliff's Edge Bristol-Myers Squibb changed its huge patent cliff into two smaller falls with a larger ledge in the middle. |
The Motley Fool
September 17, 2008
Brian Orelli |
IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business. |
The Motley Fool
May 1, 2007
Brian Lawler |
Bristol-Myers Stops Spinning in Place Bristol-Myers releases first-quarter financial results. Investors, take note. |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
The Motley Fool
March 30, 2009
Brian Orelli |
Here's Some Cash. Go Away. Bristol-Myers Squibb has to pay $2.1 million to settle a Federal Trade Commission investigation. |
The Motley Fool
April 29, 2004
Brian Gorman |
Merck, Bristol-Myers Team Up Their agreement to commercialize a diabetes drug reflects intense sales competition in the industry. |
The Motley Fool
December 14, 2004
Brian Gorman |
Bristol-Myers' Smart Moves Although problems still hang over the company, Bristol-Myers is paving the way for recovery. In the meantime investors will surely be jittery. |
The Motley Fool
November 17, 2009
Brian Orelli |
Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount |
